Clostridioides difficile is a gram-positive bacteria that causes disease in persons with dysbiosis of the gut microbiota and has been listed as an urgent threat due to the emergence of resistance.
Researchers from presented preclinical data for AVX-70371, a novel therapeutic vaccine being developed for the treatment of chronic hepatitis B virus (HBV) infection.
Researchers from the University of Washington are developing new antibiotics targeting bacterial methionyl-tRNA synthetase (MetRS). This enzyme is responsible for charging tRNA(met) with methionine and integral to protein synthesis.
Researchers from Emory University, the U.S. CDC and collaborators have identified a broad-spectrum antiviral agent able to combat highly pathogenic arenaviruses. The compound, a ribonucleoside analogue that acts through RdRp inhibition, exhibited a good pharmacokinetic profile, oral bioavailability and tissue distribution in guinea pigs, while protecting animals from lethal challenges with Lassa and Junín viruses, even at very low doses.
Nimbus Saturn Inc. has identified proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase-binding moiety covalently linked to a mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1)-targeting moiety linked via a linker.
Enanta Pharmaceuticals Inc. has released preclinical pharmacokinetics (PK) data for EDP-514, a potent and selective class II core assembly modulator in phase I development for the oral treatment of hepatitis B.
A joint Korea Research Institute of Chemical Technology and Novartis AG patent describes antiviral 1,3-di-oxo-indene compounds reported to be useful for the treatment of asthma, chronic obstructive pulmonary disease, diabetes, hepatitis A, viral infection, myocarditis, myositis and pancreatitis, among others.
Epigenic Therapeutics Inc. has received clinical trial application (CTA) approval from the New Zealand Medicines and Medical Devices Safety Authority (Medsafe) and the Health and Disability Ethics Committees (HDEC) to initiate a clinical trial for EPI-003, an investigational, liver-targeting antiviral therapy for chronic hepatitis B virus (HBV) infection.
RSS
